MAVYRET is a medication used to treat chronic hepatitis C virus (HCV) infection in adults. It is a combination of two antiviral drugs, glecaprevir and pibrentasvir, which work together to target and inhibit the replication of the HCV. MAVYRET is taken orally once daily for a specified duration, depending on the patient's HCV genotype and treatment history. It has been proven to be highly effective in achieving sustained virologic response, which means clearing the HCV from the body, and has a favorable safety profile.
Sofosbuvir-velpatasvir is a combination medication used for the treatment of chronic hepatitis C virus (HCV) infection. It contains two active ingredients, sofosbuvir and velpatasvir, which work together to inhibit the replication of the HCV virus and prevent its spread in the body. This medication is typically prescribed for patients with specific genotypes of HCV and has shown high efficacy rates in achieving sustained virologic response, leading to improved liver function and reduced risk of liver-related complications. Sofosbuvir-velpatasvir is usually taken orally once a day for a specified duration as directed by a healthcare professional.
